Monitoring vascular disrupting therapy in a rabbit liver tumor model: Relationship between tumor perfusion parameters at IVIM Diffusion-weighted MR imaging and those at dynamic contrast-enhanced MR Imaging1

Radiology

Volumn 278, Issue 1, 2016, Pages 104-113

  Joo, Ijin ^a   Lee, Jeong Min ^a   Grimm, Robert ^b   Han, Joon Koo ^a   Choi, Byung Ihn ^a  

^a Seoul National University Hospital   (South Korea)

^b SIEMENS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPHENONE DERIVATIVE; CONTRAST MEDIUM; N-(4-(3-(1H-1,2,4-TRIAZOL-1-YL)-4-(3,4,5-TRIMETHOXYBENZOYL)PHENYL)THIAZOL-2-YL)-2-AMINO-3-METHYLBUTANAMIDE; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VALINE;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIFFUSION WEIGHTED IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMAGE PROCESSING; LIVER NEOPLASMS, EXPERIMENTAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RABBIT; VASCULARIZATION;

ANIMALS; BENZOPHENONES; BIOMARKERS, TUMOR; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; RABBITS; TUMOR NECROSIS FACTOR-ALPHA; VALINE;

EID: 84952916487     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015141974     Document Type: Article

References (45)

1. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer 2010;116(8):1859-1871.
2. Salmon BA, Salmon HW, Siemann DW. Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer 2007;43(10):1622-1629.
3. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst 2005;97(3):172-187.
4. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT: Are measurements from two commercial software packages interchangeable? Radiology 2007;242(3):777-782.
5. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 2005; 7(8):779-787.
6. Wang H, Li J, Chen F, et al. Morphological, functional and metabolic imaging biomarkers: Assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 2010;20(8):2013-2026.
7. Wang H, Cona MM, Chen F, et al. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anticancer Drugs 2012;23(1):12-21.
8. OConnor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96(2): 189-195.
9. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23(24):5464-5473.
10. Leach MO, Morgan B, Tofts PS, et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 2012; 22(7):1451-1464.
11. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: Application to diffusion and perfusion in neurologic disorders. Radiology 1986;161(2):401-407.
12. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011;196(6):1351-1361.
13. Rheinheimer S, Stieltjes B, Schneider F, et al. Investigation of renal lesions by diffusionweighted magnetic resonance imaging applying intravoxel incoherent motion-derived parameters-initial experience. Eur J Radiol 2012;81(3):e310-e316.
14. Shinmoto H, Tamura C, Soga S, et al. An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer. AJR Am J Roentgenol 2012;199(4):W496-W500.
15. Kang KM, Lee JM, Yoon JH, Kiefer B, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for characterization of focal pancreatic lesions. Radiology 2014;270(2):444-453.
16. Padhani AR, Liu G, Koh DM, et al. Diffusionweighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.
17. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010; 37(Suppl 1):S164-S182.
18. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237(2):492-499.
19. Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014;272(2): 417-426.
20. Kim KW, Lee JM, Jeon YS, et al. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs 2013; 31(5):1097-1106.
21. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4(3):141-148.
22. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92(9):1599-1610.
23. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48(8):2179-2183.
24. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19(1A):189-195.
25. Duda DG. Molecular biomarkers of response to antiangiogenic therapy for cancer. ISRN Cell Biol 2012;2012. Pii: 587259.
26. Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrastenhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011;18(8):2192-2199.
27. Kim KW, Lee JM, Jeon YS, et al. Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). Eur Radiol 2013;23(5):1352-1360.
28. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168(2):497-505.
29. Sigmund EE, Cho GY, Kim S, et al. Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer. Magn Reson Med 2011;65(5):1437-1447.
30. Mross K, Fasol U, Frost A, et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: A randomized phase I study. J Angiogenes Res 2009;1:5.
31. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17(2): 357-367.
32. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3): 223-232.
33. Luypaert R, Sourbron S, de Mey J. Validity of perfusion parameters obtained using the modified Tofts model: A simulation study. Magn Reson Med 2011;65(5):1491-1497.
34. Chikui T, Kitamoto E, Kawano S, et al. Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012;36(3):589-597.
35. Iellamo F, Legramante JM, Raimondi G, Castrucci F, Massaro M, Peruzzi G. Evaluation of reproducibility of spontaneous baroreflex sensitivity at rest and during laboratory tests. J Hypertens 1996;14(9):1099-1104.
36. Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation 2008; 118(19):2005-2010.
37. Chan YH. Biostatistics 301A. Repeated measurement analysis (mixed models). Singapore Med J 2004;45(10):456-461.
38. Shao H, Ni Y, Zhang J, et al. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors. PLoS ONE 2013;8(12): e82649.
39. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26(28):4572-4578.
40. Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011;55(4):858-865.
41. McPhail LD, McIntyre DJ, Ludwig C, et al. Rat tumor response to the vascular-disrupting agent 5, 6-dimethylxanthenone-4-Acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 2006;8(3):199-206.
42. Lee HJ, Rha SY, Chung YE, et al. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Magn Reson Med 2014;71(4):1554-1558.
43. Sigmund EE, Vivier PH, Sui D, et al. Intravoxel incoherent motion and diffusion-Tensor imaging in renal tissue under hydration and furosemide flow challenges. Radiology 2012;263(3):758-769.
44. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010;31(3):589-600.
45. Chandarana H, Kang SK, Wong S, et al. Diffusion-weighted intravoxel incoherent motion imaging of renal tumors with histopathologic correlation. Invest Radiol 2012;47(12):688-696.